Puma Biotechnology, Inc. (PBYI)

The investment case here is severely compromised by a brutal multi-year price trajectory. Over the last nine years, the stock has lost over 90% of its value, with the most recent annual performance showing a decline. While the company currently boasts a healthy balance sheet with low debt and decent cash flow, the market has clearly priced in a fundamental deterioration that is not being offset by recent operational improvements. The revenue growth is negative, and the operating margins remain in the red, indicating the core business is struggling to generate profit despite sales. This disconnect between the pristine balance sheet and the collapsing share price suggests the market sees a value trap or a business in terminal decline. The options market reinforces this bearish sentiment, with traders aggressively buying protection at lower price levels while avoiding calls entirely. Without a dramatic reversal in profitability or a massive catalyst to restore investor confidence, the long-term outlook remains bleak, and the short-term momentum is likely to continue downward as the weight of the past decade's losses presses on the current price.